Global Tobacco and Nicotine Forum (GTNF) 2022

Sep.27.2022
Global Tobacco and Nicotine Forum (GTNF) 2022
GTNF, a global forum for tobacco and nicotine industries, will hold its signing ceremony on September 27th in Washington.

The Global Tobacco and Nicotine Forum (GTNF) will kick off its signing ceremony at the Four Seasons Hotel in Washington, D.C. on September 27th at 11:00 a.m. EST (September 28th at 11:00 p.m. Beijing time) . Since its inauguration in Rio de Janeiro, Brazil in 2008, GTNF has served as a platform for global public health experts, government officials, and professionals and investors in the tobacco and nicotine industries to exchange ideas. As a leading nicotine industry forum, numerous Chinese companies will participate in this year's event.


The conference is scheduled to take place from September 27 to September 29, lasting three days. Chinese businesses will participate in the panel discussion on September 29 under the theme of "Products: Innovation for Tomorrow." Speakers from leading Chinese companies such as Smoore Technology, Zhenwei Biology Technology, Dr. Pen Technology, Jetway Technologies, and a representative from Yunnan University's NGP Industry Research team will join hundreds of scientists, public health experts, government officials, industry leaders, and media professionals from around the world to discuss hot topics in the industry such as "low-temperature atomization", "next-generation nicotine salts", and "compatibility between e-juice and hardware" from both the enterprise and user perspectives.


Several Chinese companies were invited to participate in the forum, and many of them also provided sponsorship for the event.


These enterprises primarily include:


Companies such as Simor Technology Co., Ltd., Zhenwei Biotechnology Co., Ltd., Zhuolineng Technology Co., Ltd., Jiyi Technology Co., Ltd., Xinyikang Technology Co., Ltd., and Michael Technology Co., Ltd.


2FIRSTS will send on-site reporters for continuous coverage. For more information, click on the link below to access the GTNF forum topic.


Statement:


This article is sourced from third-party information and is provided for industry professionals for the purposes of exchange and learning.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness or accuracy of the content. The compilation of this article is only intended for communication and research within the industry.


Due to limitations in our translation abilities, the translated article may not accurately convey the same meaning as the original. Please refer to the original article for accuracy.


2FIRSTS aligns completely with the stance and positions of the Chinese government on all domestic, Hong Kong, Macau, Taiwan, and foreign matters.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for removal.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands reported first-quarter 2026 results on May 7, covering the period ended March 31, 2026. Total consolidated net sales were $124.3 million, up 16.8% year on year. Gross profit was $68.3 million, up 14.6%, while net income fell 19.0% to $11.7 million. Adjusted EBITDA declined 6.5% to $25.9 million.
May.08 by 2FIRSTS.ai
Smoore International Q1 Results: Enterprise-Focused Business Up 48.6% Year-on-Year, Proprietary E-Vapor Brand Business Up 14.3%
Smoore International Q1 Results: Enterprise-Focused Business Up 48.6% Year-on-Year, Proprietary E-Vapor Brand Business Up 14.3%
Smoore International reported its Q1 financial results, with revenue for the period reaching RMB3.856 billion, up 41.7% year-on-year, and net profit (profit for the period) totaling RMB262.5 million, up 36.6% year-on-year. Revenue from its enterprise-focused business was RMB3.2674 billion, representing a 48.6% increase from RMB2.1989 billion in the same period last year. Revenue from its proprietary brand business was RMB588.6 million, up 12.6% from RMB522.6 million a year earlier.
Apr.10 by 2FIRSTS.ai
Jeju Health Center to Apply Conventional Tobacco Rules to Liquid E-Cigarettes From April 24
Jeju Health Center to Apply Conventional Tobacco Rules to Liquid E-Cigarettes From April 24
Jeju Health Center said it will apply the same regulations used for conventional tobacco products to all tobacco products, including liquid e-cigarettes, from April 24, while also strengthening public guidance and smoke-free zone management.
Apr.21 by 2FIRSTS.ai
Product | Labeled “Built in the USA” + 33mL Total E-Liquid, iJOY XP100K E-Cigarette Launched in the U.S.
Product | Labeled “Built in the USA” + 33mL Total E-Liquid, iJOY XP100K E-Cigarette Launched in the U.S.
iJOY Launches New IJOY XP100K E-Cigarette on Official Website. The product adopts a combined structure of “pod + power bank + refill e-liquid bottle,” comes pre-filled with 18mL of e-liquid and includes 15mL of refill liquid. It is officially claimed to deliver up to approximately 100,000 puffs, and its packaging bears the wording “BUILT IN THE USA.” It has already gone on sale through some online channels in the United States, with the kit priced at US$19.99.
Apr.08 by 2FIRSTS.ai
WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
Ahead of World No Tobacco Day 2026, WHO released its first global report on nicotine pouches, warning that rapid market growth, youth-oriented marketing and weak regulation are converging. 2Firsts views the report as an important warning, but not a complete risk assessment, with harm-reduction questions still unresolved.
Special Report
May.17
FDA and NIH Release New Wave 8 Restricted-Use PATH Study Data Files
FDA and NIH Release New Wave 8 Restricted-Use PATH Study Data Files
FDA’s Center for Tobacco Products and NIH’s National Institute on Drug Abuse announced that new Wave 8 restricted-use data files from the PATH Study are now available. The files contain data collected between January 2024 and December 2024, including questionnaire data, location characteristics data, and state identifier data.
Apr.17 by 2FIRSTS.ai